To assess the rate of patients with early breast cancer treated with NAT, to understand the criteria for selecting patients for NAT and to describe the types of therapies administered, an analysis was performed in stage I-II-III patients with breast cancer enrolled in the BRIDE study. The gene discussed is BRD2; the disease is breast cancer.